Heart rate variability as a biomarker of anxious depression response to antidepressant medication
Why the study?
Does pretreatment heart rate variability predict treatment outcomes of antidepressant medication in patients with major depressive disorder?
Population
1,008 patients with current nonpsychotic major depressive disorder, including 309 with anxious depression…
Comparison
Antidepressant medication managed by usual… vs null
Design
RCT, randomized
Follow-up
8 weeks
Authors
Discussion
Loading...
Member takes
Overview
May guide personalized antidepressant selection by HRV and anxiety subtype in MDD; extends RCT evidence for pretreatment HRV as a response biomarker.
Structured PICO
Does pretreatment heart rate variability predict treatment outcomes of antidepressant medication in patients with major depressive disorder?
P
Population
1,008 patients with current nonpsychotic major depressive disorder (MDD), including 309 with anxious depression and 413 with nonanxious depression (722 completers).
I
Intervention
Antidepressant medication (escitalopram, sertraline, or venlafaxine-extended release) managed by usual treating clinicians.
C
Comparator
null
O
Outcome
Clinician-rated depressive symptom response and remission at 8 weeks.patient reported
Pretreatment heart rate variability may serve as a useful biomarker to predict which patients with major depressive disorder will respond to standard antidepressant medications, depending on the presence of anxious depression.
Cite This Study
Kircanski et al. (2018) studied this question.